ACAD
32.3
-0.1
-0.31%
AEMD
4.86
+0.04
+0.83%
APRI
0.534
-0.008
-1.5498%
ARNA
1.72
-0.05
-2.82%
ATEC
0.221
-0.018
-7.4276%
CNAT
2.87
+0.02
+0.70%
CRXM
0.19
0.00
0.00%
CYTX
0.32
-0.02
-5.88%
DXCM
64.38
-1.58
-2.40%
GNMK
5.91
-0.16
-2.64%
HALO
10.55
-0.29
-2.68%
ILMN
134.99
-0.76
-0.56%
INNV
0.092
-0.004
-4.167%
INO
10.48
-0.7
-6.26%
ISCO
3.75
-0.1
-2.60%
ISIS
57.56
0.00
0.00%
LGND
120.87
-2.25
-1.83%
LPTN
0.233
-0.009
-3.6349%
MBVX
0.72
0.00
-0.66%
MEIP
1.4
0.00
0.00%
MNOV
6.88
-0.1
-1.43%
MRTX
20.72
-0.32
-1.52%
MSTX
0.295
-0.006
-1.8279%
NBIX
45.58
-1.32
-2.81%
NUVA
52.94
-0.16
-0.30%
ONCS
1.96
+0.01
+0.51%
ONVO
2.72
-0.03
-1.09%
OREX
0.447
-0.02
-4.201%
OTIC
14.26
-0.36
-2.46%
QDEL
17.3
-0.38
-2.15%
RCPT
231.96
0.00
0.00%
RGLS
5.84
-0.32
-5.19%
RMD
55.8
-0.7
-1.24%
SPHS
1.2
0.00
0.00%
SRNE
6.86
-0.04
-0.58%
TROV
4.02
-0.14
-3.37%
VICL
0.399
+0.004
+1.013%
VOLC
18
0.00
0.00%
ZGNX
10.25
-0.38
-3.57%
ACAD
32.3
-0.1
-0.31%
AEMD
4.86
+0.04
+0.83%
APRI
0.534
-0.008
-1.5498%
ARNA
1.72
-0.05
-2.82%
ATEC
0.221
-0.018
-7.4276%
CNAT
2.87
+0.02
+0.70%
CRXM
0.19
0.00
0.00%
CYTX
0.32
-0.02
-5.88%
DXCM
64.38
-1.58
-2.40%
GNMK
5.91
-0.16
-2.64%
HALO
10.55
-0.29
-2.68%
ILMN
134.99
-0.76
-0.56%
INNV
0.092
-0.004
-4.167%
INO
10.48
-0.7
-6.26%
ISCO
3.75
-0.1
-2.60%
ISIS
57.56
0.00
0.00%
LGND
120.87
-2.25
-1.83%
LPTN
0.233
-0.009
-3.6349%
MBVX
0.72
0.00
-0.66%
MEIP
1.4
0.00
0.00%
MNOV
6.88
-0.1
-1.43%
MRTX
20.72
-0.32
-1.52%
MSTX
0.295
-0.006
-1.8279%
NBIX
45.58
-1.32
-2.81%
NUVA
52.94
-0.16
-0.30%
ONCS
1.96
+0.01
+0.51%
ONVO
2.72
-0.03
-1.09%
OREX
0.447
-0.02
-4.201%
OTIC
14.26
-0.36
-2.46%
QDEL
17.3
-0.38
-2.15%
RCPT
231.96
0.00
0.00%
RGLS
5.84
-0.32
-5.19%
RMD
55.8
-0.7
-1.24%
SPHS
1.2
0.00
0.00%
SRNE
6.86
-0.04
-0.58%
TROV
4.02
-0.14
-3.37%
VICL
0.399
+0.004
+1.013%
VOLC
18
0.00
0.00%
ZGNX
10.25
-0.38
-3.57%
Home » Events, SDBN Events

SDBN Networking Event Featuring Fate Therapeutics & Stemgent

Submitted by on July 1, 2009 – 11:41 am

The San Diego Biotechnology Network’s July 21st event will feature Fate Therapeutics and Stemgent, two companies engaged in exciting, interdisciplinary biotechnology research in San Diego that holds direct promise for making a difference in our quality of life. Ken Batchelor, Ph.D., CSO, Fate Therapeutics, and Stephen Chang, Ph.D., CSO, Stemgent will present a short talk which will be followed by networking:

CATALYST: The Industrialization of Advanced iPSC Technology for Drug Discovery & Development

For more information visit http://sdbn.org/july

Leave a comment!

Add your comment below, or trackback from your own site. You can also Comments Feed via RSS.

Be nice. Keep it clean. Stay on topic. No spam.

You can use these tags:

<a href="" title="" rel=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong> 

This is a Gravatar-enabled weblog. To get your own globally-recognized-avatar, please register at Gravatar.

Please prove you\'re human, solve this: *